Daiichi Sankyo sees new products, Ranbaxy taking sales to $12 billion level in three years
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo is aiming to boost its group operating profit by almost 90% to ¥180 billion ($1.98 billion) in the fiscal year ending March 31st, 2013, on net sales which are seen reaching ¥1,150 billion, a 20% increase over those forecast for the year to this March 31st.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.